ISC 2025 | China’s experience with urokinase thrombolysis for acute ischemic stroke (AIS)

Wenbo Zhao, MD, PhD, Xuanwu Hospital, Beijing, China, comments on the value of urokinase thrombolysis for acute ischemic stroke (AIS) in China, highlighting the country’s accumulated experience with this treatment despite limited international recognition. Dr Zhao notes that urokinase has demonstrated reliable therapeutic effects and comparable efficacy to newer thrombolytics, but challenges remain, particularly in developing personalized dosing protocols. This interview took place at the 2025 International Stroke Conference (ISC), held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.